Download MendeleyGSK114: A selective inhibitor for elucidating the biological role of TNNI3K.
Lawhorn, B.G., Philp, J., Graves, A.P., Shewchuk, L., Holt, D.A., Gatto, G.J., Kallander, L.S.(2016) Bioorg Med Chem Lett 26: 3355-3358
- PubMed: 27246618
- DOI: https://doi.org/10.1016/j.bmcl.2016.05.033
- Primary Citation of Related Structures:
4YHT - PubMed Abstract:
A series of selective TNNI3K inhibitors were developed by modifying the hinge-binding heterocycle of a previously reported dual TNNI3K/B-Raf inhibitor. The resulting quinazoline-containing compounds exhibit a large preference (up to 250-fold) for binding to TNNI3K versus B-Raf, are useful probes for elucidating the biological pathways associated with TNNI3K, and are leads for discovering novel cardiac medicines. GSK114 emerged as a leading inhibitor, displaying significant bias (40-fold) for TNNI3K over B-Raf, exceptional broad spectrum kinase selectivity, and adequate oral exposure to enable its use in cellular and in vivo studies.
Organizational Affiliation:
Heart Failure DPU, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA. Electronic address: brian.2.lawhorn@gsk.com.
